|
|
|
Search for: "Cytogen"
REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
HSMN NewsFeed,
20 Aug 2010:
Biopharmaceuticals, Oncology, Regulatory
[Celgene, REVLIMID, lenalidomide, myelodysplastic syndrome]
|
Eisai Announces Results of Phase III Study of Dacogen(R) (Decitabine) for Injection in Acute Myeloid Leukemia (AML)
HSMN NewsFeed,
30 Jun 2010:
Biopharmaceuticals, Oncology
[Eisai, Dacogen, decitabine, acute myeloid leukemia]
|
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
HSMN NewsFeed,
4 Jun 2010:
Biopharmaceuticals, Oncology
[Novartis, Tasigna, nilotinib, Gleevec, imatinib mesylate, Ph+ CML]
|
EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region
HSMN NewsFeed,
8 Mar 2010:
Biopharmaceuticals, Personnel
[EUSA Pharma]
|
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
HSMN NewsFeed,
19 Feb 2010:
Biopharmaceuticals, Oncology
[Novartis, Tasigna, nilotinib, Ph+ CML]
|
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
HSMN NewsFeed,
8 Dec 2009:
Biopharmaceuticals, Oncology
[Novartis, Tasigna, nilotinib, Gleevec, imatinib, chronic myeloid leukemia]
|
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
HSMN NewsFeed,
7 Dec 2009:
Biopharmaceuticals, Oncology
[Millennium Pharmaceuticals, Takeda Pharmaceutical, VELCADE, bortezomib]
|
NeoGenomics Announces Executive Appointments
HSMN NewsFeed,
4 Dec 2009:
Diagnostics, Oncology, Personnel
[NeoGenomics]
|
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
HSMN NewsFeed,
20 Oct 2009:
Biopharmaceuticals, Oncology
[Novartis, Tasigna, nilotinib, Gleevec, imatinib, Ph+ CML]
|
NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test
HSMN NewsFeed,
24 Jul 2009:
Diagnostics, Oncology
[NeoGenomics, Abbott, fluorescence in situ hybridization, melanoma]
|
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
HSMN NewsFeed,
26 May 2009:
Biopharmaceuticals, Oncology
[Bristol-Myers Squibb, SPRYCEL, dasatinib, chronic myeloid leukemia]
|
Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting
HSMN NewsFeed,
11 May 2009:
Diagnostics, Neurology
[Transgenomic, Power3 Medical Products, NuroPro , Alzheimer's, Parkinson's]
|
EUSA Pharma Completes the European Launch of CAPHOSOL(R) for Prevention and Treatment of Oral Mucositis Caused by Cancer Therapy
HSMN NewsFeed,
31 Mar 2009:
Biopharmaceuticals
[EUSA Pharma, CAPHOSOL, oral mucositis]
|
REVLIMID Receives Preliminary Positive Recommendation from National Institute for Health and Clinical Excellence (NICE) for Use in the National Health Service (NHS) in England and Wales
HSMN NewsFeed,
30 Jan 2009:
Biopharmaceuticals, Oncology, Regulatory
[Celgene International Sŕrl, Celgene, REVLIMID, multiple myeloma]
|
HistoRx Names Kate Adams Vice President, Diagnostics Marketing and Retains Steve Chubb as Strategic Advisor
HSMN NewsFeed,
17 Dec 2008:
Diagnostics, Personnel
[HistoRx]
|
Cancer Drug Vidaza(R) Receives Positive Opinion from European Regulatory Authority for Treatment of MDS and AML
HSMN NewsFeed,
24 Oct 2008:
Biopharmaceuticals, Regulatory
[Celgene, Celgene International Sŕrl, VIDAZA, azacitidine]
|
Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization from Health Canada for Treatment of Multiple Myeloma
HSMN NewsFeed,
6 Oct 2008:
Biopharmaceuticals, Oncology, Regulatory
[Celgene International Sarl, REVLIMI, lenalidomide, multiple myeloma]
|
Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
HSMN NewsFeed,
25 Aug 2008:
Biopharmaceuticals, Personnel
[Ikaria Holdings]
|
VIDAZA(R) Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS
HSMN NewsFeed,
21 Aug 2008:
Biopharmaceuticals, Oncology, FDA
[Celgene, myelodysplastic syndromes, VIDAZA]
|
The DNA Repair Company Strengthens Operations and Development Capabilities with Addition of Two Senior Officials
HSMN NewsFeed,
29 Jul 2008:
Oncology, Personnel
[DNA Repair Company, personalized medicine]
|
Advaxis Incorporated Receives List of Questions from the U.S. Food and Drug Administration
HSMN NewsFeed,
29 Jul 2008:
Biopharmaceuticals, Oncology, FDA
[Advaxis, Lovaxin C, Cervical Intraepithelial Neoplasia, cancer vaccine]
|
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
HSMN NewsFeed,
1 Jul 2008:
Biopharmaceuticals, Oncology
[Eisai, Dacogen, decitabine, myelodysplastic syndromes]
|
SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
HSMN NewsFeed,
1 Jul 2008:
Biopharmaceuticals, Oncology
[SuperGen, Dacogen, decitabine, myelodysplastic syndromes]
|
Study of VIDAZA(R) in Higher-Risk Myelodysplastic Syndrome Patients Demonstrates Improved Overall Survival
HSMN NewsFeed,
3 Jun 2008:
Biopharmaceuticals, Oncology
[Celgene, VIDAZA, myelodysplastic syndromes]
|
Celgene Withdraws European Union (EU) Marketing Authorization Application for Lenalidomide in Deletion-5Q Myelodysplastic Syndromes
HSMN NewsFeed,
2 Jun 2008:
Biopharmaceuticals, Oncology, Regulatory
[Celgene, REVLIMID, Lenalidomide, myelodysplastic syndromes]
|
Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
HSMN NewsFeed,
29 May 2008:
Biopharmaceuticals, FDA
[Wyeth Pharmaceuticals, TYGACIL, tigecycline, community-acquired pneumonia]
|
Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
HSMN NewsFeed,
19 May 2008:
Biopharmaceuticals, Oncology
[Novartis Pharmaceuticals UK, Tasigna, Philadelphia chromosome, chronic myeloid]
|
EUSA Pharma Completes Acquisition Of Cytogen Corporation
HSMN NewsFeed,
9 May 2008:
Biopharmaceuticals, Mergers & Acquisitions
[EUSA Pharma, Cytogen]
|
VioQuest Pharmaceuticals Names Vernon L. Alvarez, Ph.D. as Vice President, Research & Development and Announces Resignation of Chief Scientific Officer
HSMN NewsFeed,
14 Apr 2008:
Biopharmaceuticals, Personnel
[VioQuest Pharmaceuticals]
|
EUSA Pharma to Acquire US Specialty Oncology Company Cytogen
HSMN NewsFeed,
11 Mar 2008:
Biopharmaceuticals, Mergers & Acquisitions
[EUSA Pharma, Cytogen]
|
EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
HSMN NewsFeed,
27 Feb 2008:
Biopharmaceuticals, Oncology, Regulatory
[EpiCept, Ceplene, histamine dihydrochloride, Acute Myeloid Leukemia]
|
Lenalidomide (REVLIMID(R)) Receives Orphan Drug Status in Japan for Multiple Indications
HSMN NewsFeed,
19 Feb 2008:
Biopharmaceuticals, Oncology, Regulatory
[Celgene International Sarl, lenalidomide, orphan drug designation]
|
Cubist Pharmaceuticals Names Steven C. Gilman, Ph.D., as Senior Vice President, Discovery and Non-Clinical Development and Chief Scientific Officer
HSMN NewsFeed,
12 Feb 2008:
Biopharmaceuticals, Personnel
[Cubist Pharmaceuticals]
|
Celgene Reports on REVLIMID(R) (Lenalidomide) Global Regulatory Developments in Multiple Myeloma and Deletion 5Q Myelodysplastic Syndromes
HSMN NewsFeed,
24 Jan 2008:
Biopharmaceuticals, Regulatory
[Celgene International Sarl, REVLIMID, multiple myeloma, Lenalidomide]
|
Ampersand Ventures Invests in Signature Genomic Laboratories
HSMN NewsFeed,
23 Jan 2008:
Diagnostics, Venture Capital
[Signature Genomic Laboratories, Ampersand Ventures, SignatureChip]
|
Joseph A. Mollica Named Chairman of Celator(R) Pharmaceuticals Board of Directors
HSMN NewsFeed,
14 Jan 2008:
Biopharmaceuticals, Personnel
[Celator Pharmaceuticals]
|
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
HSMN NewsFeed,
14 Jan 2008:
Biopharmaceuticals, Oncology
[Pharmion, Vidaza, azacitidine, Myelodysplastic Syndromes]
|
Pharmos Corporation Announces Board and Management Changes
HSMN NewsFeed,
3 Jan 2008:
Biopharmaceuticals, Personnel
[Pharmos]
|
SWOG Phase III Trial Reports REVLIMID(R) (lenalidomide) Plus Dexamethasone Achieves Superior Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients
HSMN NewsFeed,
9 Dec 2007:
Biopharmaceuticals, Oncology
[Celgene, Celgene International Sŕrl, REVLIMID, lenalidomide, multiple myeloma]
|
REVLIMID(R) (Lenalidomide) Plus Low-Dose Dexamethasone Achieves Unprecedented Survival Rate in ECOG Phase III Trial in Newly Diagnosed Multiple Myeloma
HSMN NewsFeed,
9 Dec 2007:
Biopharmaceuticals, Oncology
[Celgene, Celgene International Sŕrl, REVLIMID, lenalidomide, multiple myeloma]
|
Lenalidomide (REVLIMID(R)) Receives Orphan Medicinal Product Designation from the European Commission for Chronic Lymphocytic Leukemia
HSMN NewsFeed,
30 Nov 2007:
Biopharmaceuticals, Regulatory
[Celgene, lenalidomide, REVLIMID, chronic lymphocytic leukemia]
|
Tasigna(R) gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies
HSMN NewsFeed,
28 Nov 2007:
Biopharmaceuticals, Oncology, Regulatory
[Novartis, Tasigna, nilotinib, leukemia]
|
China Medical Technologies Announces Changes in Board of Directors and Appointment of Chief Technology Officer
HSMN NewsFeed,
19 Nov 2007:
Devices, Personnel
[China Medical Technologies]
|
VioQuest Appoints Michael D. Becker as President and Chief Executive Officer
HSMN NewsFeed,
14 Nov 2007:
Biopharmaceuticals, Personnel
[VioQuest Pharmaceuticals]
|
Cancer Drug REVLIMID(R) Receives Recommendation for Approval from Australian Drug Evaluation Committee for Treatment of Multiple Myeloma
HSMN NewsFeed,
12 Nov 2007:
Biopharmaceuticals, Oncology, Regulatory
[Celgene, Celgene International Sarl, REVLIMID, lenalidomide, multiple myeloma]
|
Cytogen Announces Executive Management Changes
HSMN NewsFeed,
12 Nov 2007:
Biopharmaceuticals, Personnel
[Cytogen, Kevin Lokay]
|
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
HSMN NewsFeed,
8 Nov 2007:
Biopharmaceuticals, FDA, Oncology
[Bristol-Myers Squibb, SPRYCEL, Dasatinib, CML]
|
Tasigna(R) receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
HSMN NewsFeed,
29 Oct 2007:
Biopharmaceuticals, Oncology, FDA
[Novartis, Tasigna, nilotinib, leukemia]
|
FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
HSMN NewsFeed,
24 Oct 2007:
Biopharmaceuticals
[Wyeth, Tygacil, tigecycline, community-acquired pneumonia]
|
Transgenomic Names New Sr. VP of Sales and Marketing
HSMN NewsFeed,
10 Oct 2007:
Diagnostics, Personnel
[Transgenomic]
|
Celsion Bolsters Clinical Development Team
HSMN NewsFeed,
27 Sep 2007:
Biopharmaceuticals, Personnel
[Celsion]
|
CombiMatrix Molecular Diagnostics Launches HemeScan MDS for the Management and Diagnosis of Myelodysplastic Syndromes
HSMN NewsFeed,
25 Sep 2007:
Diagnostics, Oncology
[CombiMatrix, HemeScan, myelodysplastic syndromes]
|
Updated REVLIMID(R) Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic Leukemia
HSMN NewsFeed,
17 Sep 2007:
Biopharmaceuticals, Oncology
[Celgene, REVLIMID, lenalidomide, Chronic Lymphocytic Leukemia]
|
Xenomics Announces Agreement with Ipsogen for Diagnostic Assays of Leukemia
HSMN NewsFeed,
17 Sep 2007:
Diagnostics, Oncology, Licensing
[Xenomics, Ipsogen]
|
NCCN Updates Dermatofibrosarcoma Protuberans Guidelines
HSMN NewsFeed,
11 Sep 2007:
Biopharmaceuticals, Oncology
[NCCN, Novartis, Gleevec, imatinib, Dermatofibrosarcoma Protuberans]
|
CytoGenix Announces Hiring of New Chief Financial Officer
HSMN NewsFeed,
7 Sep 2007:
Biopharmaceuticals, Personnel
[CytoGenix]
|
Oral Cancer Drug REVLIMID(R) Receives Swissmedic Approval in Switzerland for Treatment of Multiple Myeloma
HSMN NewsFeed,
4 Sep 2007:
Biopharmaceuticals, Regulatory, Oncology
[Celgene International Sarl, Celgene, REVLIMID, lenalidomide, multiple myeloma]
|
Bioenvision Provides Evoltra(R) (clofarabine) Regulatory Update
HSMN NewsFeed,
16 Aug 2007:
Biopharmaceuticals, Oncology, Regulatory
[Bioenvision, Evoltra, clofarabine, acute myeloid leukaemia]
|
CombiMatrix Molecular Diagnostics Launches HemeScan(TM) Ploidy Test for the Management of Acute Lymphoblastic Leukemia
HSMN NewsFeed,
25 Jun 2007:
Diagnostics, Oncology
[Acacia Research, CombiMatrix Molecular Diagnostics, HemeScan, leukemia]
|
REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
HSMN NewsFeed,
19 Jun 2007:
Biopharmaceuticals, Oncology, Regulatory
[Celgene, REVLIMID, lenalidomide, multiple myeloma]
|
Cytogen Announces New Sales and Marketing Leadership with the Appointment of Stephen A. Ross
HSMN NewsFeed,
11 Jun 2007:
Biopharmaceuticals, Personnel
[Cytogen]
|
INNOVIVE Pharmaceuticals Presents Additional Phase I Data on INNO-406 for Treatment of Gleevec-Resistant or Intolerant Chronic Myelogenous Leukemia at the American Society of Clinical Oncology Annual Meeting
HSMN NewsFeed,
2 Jun 2007:
Biopharmaceuticals, Oncology
[INNOVIVE Pharmaceuticals, INNO-406, chronic myelogenous leukemia]
|
Xanthus Presents Phase 2 Data Showing Xanafide is Associated with Complete Remissions in Secondary AML
HSMN NewsFeed,
2 Jun 2007:
Biopharmaceuticals, Oncology
[Xanthus Pharmaceuticals, Xanafide, amonafide, acute myeloid leukemia]
|
Outcomes Data Continue to Demonstrate Value of Cytogen's PROSTASCINT(R) to Predict Prognosis in Prostate Cancer
HSMN NewsFeed,
22 May 2007:
Biopharmaceuticals, Oncology
[Cytogen, PROSTASCINT, capromab pendetide, prostate cancer]
|
SWOG Phase III Newly Diagnosed Multiple Myeloma Trial (S0232) Closed and Patients Given Choice to Switch to REVLIMID(R) Plus Dexamethasone
HSMN NewsFeed,
15 May 2007:
Biopharmaceuticals, Oncology
[Celgene, REVLIMID, lenalidomide, dexamethasone, multiple myeloma]
|
Enzo Biochem Announces Supply and Royalty Bearing Cross-Licensing Agreements with Abbott
HSMN NewsFeed,
3 May 2007:
Diagnostics, Licensing
[Enzo Biochem, Abbott, fluorescence in situ hybridization]
|
ActivBiotics, Inc. Appoints Steven C. Gilman Chairman and CEO
HSMN NewsFeed,
1 May 2007:
Biopharmaceuticals, Personnel
[ActivBiotics]
|
Advaxis Completes Dosing and Enrollment of Third Cohort of Patients in Phase I/II Cervical Cancer Vaccine Trial
HSMN NewsFeed,
17 Apr 2007:
Biopharmacetuicals, Oncology
[Advaxis, Lovaxin C, cervical cancer vaccine]
|
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
HSMN NewsFeed,
4 Apr 2007:
Biopharmaceuticals, Oncology
[Celgene, ECOG, lenalidomide, REVLIMID]
|
Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for Treatment of Multiple Myeloma From European Medicines Agency
HSMN NewsFeed,
23 Mar 2007:
Biopharmaceuticals, Oncology, Regulatory
[Celgene, REVLIMID, lenalidomide, multiple myeloma]
|
Irvine Scientific Launches Their New SIS/AI Catheter
HSMN NewsFeed,
16 Mar 2007:
Devices, FDA
[Irvine Scientific, SIS/AI Catheter, Sonohysterography, Intrauterine Insemination]
|
Advanced Magnetics Announces Settlement of Lawsuit with Cytogen Corporation
HSMN NewsFeed,
15 Feb 2007:
Biopharmaceuticals, Radiology, Licensing, Litigation
[Advanced Magnetics, Cytogen, Combidex, magnetic resonance imaging]
|
Clinical Data Supporting Development of ChemGenex's Ceflatonin(R) in Imatinib-Resistant CML Published in Cancer
HSMN NewsFeed,
14 Feb 2007:
Biopharmaceuticals, Oncology
[ChemGenex Pharmaceuticals, Ceflatonin, Gleevec, chronic myeloid leukemia]
|
Seven-Year Survival Data Demonstrate use of Cytogen's PROSTASCINT(R) Independently Predicts Recurrence of Prostate Cancer
HSMN NewsFeed,
8 Feb 2007:
Biopharmaceuticals, Radiology, Oncology
[Cytogen, PROSTASCINT, brachytherapy, prostate cancer, imaging]
|
Bioenvision Files with EMeA for Label Extension of Evoltra(R)
HSMN NewsFeed,
7 Feb 2007:
Biopharmaceuticals, Oncology, Regulatory
[Bioenvision, Evoltra, clofarabine, acute myeloid leukemia]
|
FDA Clears BioView Duet(TM) System for Automated FISH Scanning of Breast Cancer Tissue Specimens
HSMN NewsFeed,
25 Jan 2007:
Diagnostics, Oncology, FDA
[BioView, BioView Duet, fluorescence in situ hybridization]
|
European Association of Nuclear Medicine Journal Article Reports New Data Regarding Administration of QUADRAMET(R) with Chemotherapy in Hormone Refractory Prostate Cancer Patients
HSMN NewsFeed,
25 Jan 2007:
Biopharmaceuticals, Oncology
[Cytogen, QUADRAMET, samarium Sm-153, prostate cancer]
|
NeoGenomics, Inc. Announces the Appointment of Robert J. Feeney, Ph.D. as Vice President of Sales and Marketing
HSMN NewsFeed,
9 Jan 2007:
Diagnostics, Personnel
[NeoGenomics]
|
INNOVIVE Pharmaceuticals Announces Receipt of FDA Orphan Drug Designation for INNO-406 for the Treatment of Chronic Myelogenous Leukemia
HSMN NewsFeed,
4 Jan 2007:
Biopharmaceuticals, Oncology, FDA
[INNOVIVE Pharmaceuticals, orphan drug designation, INNO-406]
|
Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN(R) Clinical Practice Guidelines
HSMN NewsFeed,
4 Jan 2007:
Biopharmaceuticals, Oncology
[Cytogen, NCCN, PROSTASCINT, capromab pendetide, prostate cancer]
|
Advaxis Names Thomas A. Moore to Serve as CEO and Chairman of the Board
HSMN NewsFeed,
18 Dec 2006:
Biopharmaceuticals, Personnel
[Advaxis, Listeria, cancer vaccine]
|
American Cancer Society Journal Article Reports New Data Regarding Repeated Administration of QUADRAMET(R)
HSMN NewsFeed,
18 Dec 2006:
Biopharmaceuticals, Oncology
[Cytogen, QUADRAMET]
|
INNOVIVE Pharmaceuticals Presents Data on Oncology Drug Programs in Chronic Myelogenous Leukemia and Acute Myelogenous Leukemia at American Society of Hematology 48th Annual Meeting
HSMN NewsFeed,
12 Dec 2006:
Biopharmaceuticals, Oncology
[INNOVIVE Pharmaceuticals, Chronic Myelogenous Leukemia]
|
New Evoltra(R) Data Shows Impressive Response and Survival Rates
HSMN NewsFeed,
11 Dec 2006:
Biopharmaceuticals, Oncology
[Bioenvision, Evoltra, BIOV-121]
|
Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped by Gleevec(R)
HSMN NewsFeed,
11 Dec 2006:
Biopharmaceuticals, Oncology
[Novartis Pharmaceuticals, Tasigna, nilotinib, chronic myeloid leukemia]
|
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
HSMN NewsFeed,
8 Dec 2006:
Biopharmaceuticals, Oncology
[Celgene, REVLIMID, lenalidomide, multiple myeloma, lymphoma, leukemia]
|
Advanced Magnetics, Inc. Announces European Partner Files Marketing Authorization Application for Combidex(R) With EMEA
HSMN NewsFeed,
6 Dec 2006:
Biopharmaceuticals, Regulatory, Radiology
[Advanced Magnetics, Combidex, molecular imaging agent]
|
Abbott Introduces CE-Marked DNA Tests in Europe for the Detection of Chromosomal Abnormalities Associated With Leukemia
HSMN NewsFeed,
4 Dec 2006:
Diagnostics, Oncology
[Abbott, Vysis, fluorescence in situ hybridization]
|
Genzyme Begins Phase 2 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia
HSMN NewsFeed,
27 Nov 2006:
Biopharmaceuticals, Oncology
[Genzyme, Clolar, clofarabine, acute myelogenous leukemia]
|
Cytogen Appoints Kevin Bratton New Chief Financial Officer
HSMN NewsFeed,
26 Oct 2006:
Biopharmaceuticals, Oncology, Personnel
[Cytogen]
|
Micromet, Inc. Expands Management and Appoints Christopher P. Schnittker as Senior Vice President and Chief Financial Officer
HSMN NewsFeed,
12 Oct 2006:
Biopharmaceuticals, Personnel
[Micromet]
|
Cytogen Acquires North American Marketing Rights to CAPHOSOL(R) for Treatment of Both Oral Mucositis and Dry Mouth
HSMN NewsFeed,
11 Oct 2006:
Biopharmaceuticals, Licensing
[Cytogen, InPharma AS, CAPHOSOL]
|
Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies
HSMN NewsFeed,
2 Oct 2006:
Biopharmaceuticals, Oncology
[Celgene, REVLIMID, lenalidomide, non-Hodgkins lymphoma]
|
EKR Therapeutics Expands Management Team
HSMN NewsFeed,
21 Sep 2006:
Biopharmaceuticals, Oncology, Personnel
[EKR Therapeutics]
|
Cancer Patients Show Reduced Pain and Lower Analgesic Consumption Following Treatment with QUADRAMET(R)
HSMN NewsFeed,
19 Sep 2006:
Biopharmaceuticals, Onoclogy
[Cytogen, QUADRAMET]
|
Combination of High Dose QUADRAMET(R) and Chemotherapy Shows Promise for Treatment of High-Risk Acute Myeloid Leukemia
HSMN NewsFeed,
18 Sep 2006:
Biopharmaceuticals, Oncology
[Cytogen, QUADRAMET, acute myeloid leukemia]
|
US LABS / Esoterix Names Two Prominent Industry Medical Experts To Chief Diagnostic Consultant and Medical Director Positions
HSMN NewsFeed,
11 Sep 2006:
Diagnostics, Personnel
[US LABS / Esoterix]
|
Cytogen Launches SOLTAMOX(TM), First Oral Liquid Formulation of Hormonal Therapy for Breast Cancer Patients
HSMN NewsFeed,
16 Aug 2006:
Biopharmaceuticals, Oncology
[Cytogen, SOLTAMOX, tamoxifen, breast cancer]
|
Cytogen Announces Initiation of Phase III Study Involving QUADRAMET(R)
HSMN NewsFeed,
26 Jul 2006:
Biopharmaceuticals, Oncology
[Cytogen, QUADRAMET, samarium]
|
Cytogen Announces Publication of Peer-Reviewed Journal Article on QUADRAMET(R)
HSMN NewsFeed,
26 Jul 2006:
Biopharmaceuticals
[Cytogen, QUADRAMET, samarium]
|
REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma
HSMN NewsFeed,
29 Jun 2006:
Biopharmaceuticals, Oncology, FDA
[Celgene, REVLIMID, lenalidomide, multiple myeloma]
|
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
HSMN NewsFeed,
28 Jun 2006:
Biopharmaceuticals, Oncology, FDA
[Bristol-Myers Squibb, SPRYCEL, CML, acute lymphoblastic leukemia]
|
New Survival Data on Evoltra(TM) (Clofarabine) in Elderly AML Reported at European Hematology Association Congress
HSMN NewsFeed,
21 Jun 2006:
Biopharmaceuticals, Oncology
[Bioenvision, Evoltra, clofarabine]
|
Cytogen Announces Departure of Chief Financial Officer
HSMN NewsFeed,
20 Jun 2006:
Biopharmaceuticals, Personnel
[Cytogen]
|
Patients With Treatment-Resistant Leukemia Achieve High Responses to Tasigna(R) (nilotinib) in First Published Clinical Trial Results
HSMN NewsFeed,
14 Jun 2006:
Biopharmaceuticals, Oncology
[Novartis, Tasigna, nilotinib, chronic myeloid leukemia, Gleevec, imatinib]
|
Cytogen and Philips Demonstrate PROSTASCINT(R) Image Acquisition and Processing Tools That Improve Efficiency and Reduce Imaging Time
HSMN NewsFeed,
8 Jun 2006:
Devices, Biopharmaceuticals, Oncology
[Royal Philips Electronics, Cytogen, PROSTASCINT]
|
Data Presented at SNM Meeting Demonstrate New Potential for PROSTASCINT(R) through Advances in Nuclear Medicine Imaging
HSMN NewsFeed,
7 Jun 2006:
Biopharmaceuticals, Oncology
[Cytogen, PROSTASCINT, capromab pendetide, prostate cancer]
|
Data Presented at SNM Meeting Demonstrate Novel Therapeutic Combinations and Applications for QUADRAMET(R)
HSMN NewsFeed,
7 Jun 2006:
Biopharmaceuticals, Oncology
[Cytogen, QUADRAMET, samarium Sm-153 lexidronam]
|
REVLIMID(R) (Lenalidomide) Evaluated as Combination Oral Treatment Regimen in Elderly Newly Diagnosed Multiple Myeloma
HSMN NewsFeed,
5 Jun 2006:
Biopharmaceuticals, Oncology
[Celgene, REVLIMID, lenalidomide]
|
Bioenvision's Evoltra(TM) (clofarabine) Prolongs Survival in Elderly AML Patients with Adverse Cytogenetics
HSMN NewsFeed,
5 Jun 2006:
Biopharmaceuticals, Oncology
[Bioenvision, BIOV-121, Evoltra, clofarabine, Acute Myeloid Leukemia]
|
Data From a Randomized Phase II Study of Dasatinib or 800 Mg/Day Imatinib- Mesylate (Gleevec(R)) Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology
HSMN NewsFeed,
3 Jun 2006:
Biopharmaceuticals, Oncology
[Bristol-Myers Squibb, dasatinib, chronic myelogenous leukemia]
|
Gleevec(R) Sets New Treatment Standard in Chronic Myeloid Leukemia With High Overall Survival, Increasing Response and Decreasing Progression
HSMN NewsFeed,
3 Jun 2006:
Biopharmaceuticals, Oncology
[Novartis, Gleevec, imatinib, IRIS study, chronic myeloid leukemia]
|
Cell Genesys Reports Long-Term Follow-Up Data From Phase 2 Trial of GVAX(R) Immunotherapy For Leukemia in Chronic Myelogenous Leukemia
HSMN NewsFeed,
3 Jun 2006:
Biopharmaceuticals, Oncology
[Cell Genesys, GVAX , chronic myelogenous leukemia]
|
Genzyme and Berlex Oncology Announce Interim Results of Campath in First-Line Study of Chronic Lymphocytic Leukemia at ASCO
HSMN NewsFeed,
3 Jun 2006:
Biopharmaceuticals, Oncology
[Genzyme, Berlex Oncology, Berlex Laboratories, Schering, CAM307, Campath]
|
Vion Pharmaceuticals Provides Update for Clinical and Preclinical Programs
HSMN NewsFeed,
31 May 2006:
Biopharmaceuticals
[Vion Pharmaceuticals, Cloretazine, VNP40101M]
|
New Study Demonstrates That Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Prostate Cancer Recurrence
HSMN NewsFeed,
22 May 2006:
Diagnostics, Urology, Oncology
[Cytogen, PSMA]
|
Prostate-Specific Membrane Antigen (PSMA) Expression in Neovasculature Associated with Renal Cell Carcinoma is Characterized
HSMN NewsFeed,
22 May 2006:
Diagnostics, Oncology, Urology
[Cytogen, PSMA]
|
Advaxis Continues Advancement of Two Listeria Vaccines Targeting Cancers Affecting Women
HSMN NewsFeed,
15 May 2006:
Biopharmaceuticals, Oncology
[Advaxis, cancer vaccine, breast cancer, ovarian cancer]
|
Cytogen Announces FDA Clears IND for CYT-500, a Monoclonal Antibody for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
HSMN NewsFeed,
8 May 2006:
Biopharmaceuticals, Oncology, FDA
[Cytogen , CYT-500, PROSTASCINT, capromab, prostate cancer]
|
U.S. FDA Approves Dacogen(TM) (Decitabine) for Injection
HSMN NewsFeed,
3 May 2006:
Biopharmaceuticals, Oncology, FDA
[MGI PHARMA, Dacogen, decitabine, myelodysplastic syndromes]
|
Cytogen and Savient Finalize Exclusive Distribution Agreement for SOLTAMOX(TM)
HSMN NewsFeed,
24 Apr 2006:
Biopharmaceuticals, Oncology, Distribution
[Cytogen, Savient Pharmaceuticals, SOLTAMOX, tamoxifen]
|
Advanced Magnetics Announces Appointment of Gerald L. Wolf, PhD, MD as Vice President of Imaging
HSMN NewsFeed,
24 Apr 2006:
Biopharmaceuticals, Personnel
[Advanced Magnetics]
|
REVLIMID(R) Marketing Authorization Application Accepted by EMEA for Review
HSMN NewsFeed,
7 Apr 2006:
Biopharmaceuticals, Oncology, Regulatory
[Celgene, REVLIMID, multiple myeloma, myelodysplastic syndromes]
|
FDA Grants Priority Review for REVLIMID(R) sNDA for Treatment of Relapsed or Refractory Multiple Myeloma
HSMN NewsFeed,
3 Mar 2006:
Biopharmaceuticals, Oncology, FDA
[Celgene, REVLIMID, lenalidomide, multiple myeloma]
|
Fredrick D. Cobb Appointed Vice President of Finance at Advaxis
HSMN NewsFeed,
28 Feb 2006:
Biopharmaceuticals, Personnel
[Advaxis]
|
Positive Findings from Clinical Studies of QUADRAMET(R) in Prostate Cancer Patients with Metastatic Bone Disease Presented at ASCO Prostate Cancer Symposium
HSMN NewsFeed,
27 Feb 2006:
Biopharmaceuticals, Oncology
[Cytogen, QUADRAMET]
|
Progenics Pharmaceuticals' HIV Drug, PRO 140, Receives FDA Fast-Track Designation
HSMN NewsFeed,
22 Feb 2006:
Biopharmaceuticals, HIV/AIDS, FDA
[Progenics Pharmaceuticals, PRO 140]
|
Progenics Announces Positive Top-Line Results from Second Pivotal Phase 3 Clinical Trial of Methylnaltrexone in Opioid-Induced Constipation
HSMN NewsFeed,
15 Feb 2006:
Biopharmaceuticals
[Progenics Pharmaceuticals, MNTX, methylnaltrexone]
|
|
|
 |
Additional items found:
The Network Archive contains
118 additional items
matching: Cytogen
<< Members - click the icon at left to display. |
|
| |
|
|
|
|
Public
Feeds 
Full text >>